GENEVA: The World Health Organization (WHO) and other aid groups on Thursday (Oct 28) issued a US$23.4 billion plan to bring COVID-19 vaccines, tests and drugs to poorer countries in the next year, appealing to leaders of the Group of Twenty (G20), who are meeting this weekend, for funding.
The ambitious plan outlines the strategy of the Access to COVID-19 Tools Accelerator (ACT-A) until September 2022, expected to include the use of an experimental oral antiviral pill made by Merck & Co for treating mild and moderate cases.
If the pill is approved by regulatory authorities, the cost could be as little as US$10 per course, the plan said, in line with a draft document seen by Reuters earlier this month.
"The request is for US$23.4 billion. That's a fair amount of money, but if you compare with the damage also done to global economy by the pandemic it is not really that much," Carl Bildt, WHO special envoy to the ACT-A, told a pre-briefing for selected journalists ahead of a press conference by WHO Director-General Tedros Adhanom Ghebreyesus.
Bildt, a former prime minister of Sweden, acknowledged that the ACT-A has struggled to secure previous financing and noted that Norway and South Africa co-chair a fundraising effort.
"So we do expect a strong signal from (the G20) coming out of the meeting in Rome over the weekend," he said.
Equal budgets of US$7 billion are earmarked for both vaccines and diagnostic tests, with a further US$5.9 billion for boosting health systems and US$3.5 billion for treatments including antivirals, corticosteroids and medical oxygen.
COVAX, the vaccines arm of the ACT-A, has delivered about 400 million COVID-19 doses to more than 140 low- and middle-income countries, where vaccination rates remain low, WHO chief scientist Soumya Swaminathan said.
"We know there are about 30 countries that are dependent on COVAX alone, they have no other source of vaccines," she said.
About 82 countries are likely to miss a WHO global target of 40 per cent vaccination coverage by year-end, but some of them could reach it if supplies start flowing, she said.
Referring to India which resumed "relatively modest" COVID-19 vaccine exports this month after suspending them in April due to its domestic epidemic, Swaminathan said: "I think these volumes coming out of India will go up significantly."
She added: "One of the things that is now interfering in a big way is the need for boosters - more and more high-income countries are going in for the booster doses, and this is now sucking up the vaccine doses as well."